Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bora Pharmaceuticals CoBORAY 70 Debt-to-Equity is 1.19 as of Dec. 2025, which is 53% above its 10-year median of 0.78. GuruFocus rates BORAY with a GF Score™ of 70/100 and a GF Value™ of $4.84 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 812 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks worse than 89.16% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Bora Pharmaceuticals Co's Debt-to-Equity or its related term are showing as below:
BORAY'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.34 Med: 0.78 Max: 1.68
Current: 1.19
During the past 13 years, the highest Debt-to-Equity Ratio of Bora Pharmaceuticals Co was 1.68. The lowest was 0.34. And the median was 0.78.
BORAY's Debt-to-Equity is ranked worse than 89.16% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs BORAY: 1.19
Bora Pharmaceuticals Co (OTCPK:BORAY) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Bora Pharmaceuticals Co Debt-to-Equity Related Terms
Bora Pharmaceuticals Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bora Pharmaceuticals Co Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Bora Pharmaceuticals Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bora Pharmaceuticals Co (BORAY) has a Debt-to-Equity of 1.19 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bora Pharmaceuticals Co and its competitors. This is 53% above median its historical median of 0.78. Over the past decade, Bora Pharmaceuticals Co's Debt-to-Equity has ranged from 0.34 to 1.68. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #724 out of 812 companies in the Drug Manufacturers industry, placing it in the top 89.2%.
Is Bora Pharmaceuticals Co's Debt-to-Equity too high?
Bora Pharmaceuticals Co's current Debt-to-Equity of 1.19 is 53% above median its 10-year median of 0.78. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 1.68. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Bora Pharmaceuticals Co's value of 1.19 is 340.7% above this industry median. Based on the distribution chart, Bora Pharmaceuticals Co ranks #724 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bora Pharmaceuticals Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's Debt-to-Equity compare to ?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #724 out of 812 companies for Debt-to-Equity. This places Bora Pharmaceuticals Co in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Bora Pharmaceuticals Co's value of 1.19 is 340.7% above this benchmark. Historically, Bora Pharmaceuticals Co's own Debt-to-Equity has ranged from 0.34 to 1.68 over the past decade. While the company's 10-year median is 0.78 vs. the industry median of 0.27, Bora Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bora Pharmaceuticals Co's current Debt-to-Equity of 1.19 is 340.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bora Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current Debt-to-Equity is 1.19, which is 53% above median its own 10-year median of 0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (BORAY) is currently considered Significantly Undervalued. The stock's GF Value™ is $4.84, compared to a current price of $2.59 — trading 46.5% below its estimated fair value. The current Debt-to-Equity is 1.19, which is 53% above median its 10-year median of 0.78 and 340.7% above the Drug Manufacturers industry median of 0.27. Bora Pharmaceuticals Co's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Bora Pharmaceuticals Co (BORAY), the current Debt-to-Equity is 1.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (BORAY) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of $2.59 is trading 46.5% below its estimated GF Value™ of $4.84.
GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for BORAY:
Debt-to-Equity: 1.19 (53% above median its 10-year median of 0.78)
GF Value™: $4.84 vs. price of $2.59 (46.5% below fair value)
Industry Position: 340.7% above the Drug Manufacturers median (#724 of 812)
No single metric tells the full story. See the BORAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
70GF Score
Get the complete analysis for BORAY
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BORAY has been successfully added to your 
